Cadrenal Therapeutics Presents New Trial Data At ISHLT Conference Demonstrating The Importance Of Anticoagulation Quality In LVAD Patients; The ARIES-HM3 Clinical Study Was Sponsored By Abbott

6/3/24 9:16:39 AM ET

$ABT

$CVKD

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ABT alert in real time by email

Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomes

PONTE VEDRA, Fla., June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.

Get the next $ABT alert in real time by email

Company	Date	Price Target	Rating	Analyst
Abbott Laboratories $ABT	10/8/2024	$130.00	Outperform	Oppenheimer
Abbott Laboratories $ABT	9/19/2024	$131.00	Overweight	Piper Sandler
Abbott Laboratories $ABT	7/30/2024		Buy → Hold	Edward Jones
Abbott Laboratories $ABT	5/30/2024	$121.00	Buy	Goldman
Cadrenal Therapeutics Inc. $CVKD	12/18/2023	$4.00	Outperform	Noble Capital Markets
Abbott Laboratories $ABT	7/21/2023		Underperform → Peer Perform	Wolfe Research
Abbott Laboratories $ABT	5/30/2023	$112.00	Overweight → Equal-Weight	Morgan Stanley
Abbott Laboratories $ABT	4/20/2023	$125.00 → $127.00	Overweight	Barclays

Cadrenal Therapeutics Presents New Trial Data At ISHLT Conference Demonstrating The Importance Of Anticoagulation Quality In LVAD Patients; The ARIES-HM3 Clinical Study Was Sponsored By Abbott

Chat with this insight

Recent Analyst Ratings for $ABT$CVKD

$ABT$CVKD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

SEC Form SC 13G/A filed by Abbott Laboratories (Amendment)

$ABT$CVKD SEC Filings

Abbott Laboratories filed SEC Form 8-K: Leadership Update

SEC Form S-3 filed by Cadrenal Therapeutics Inc.

SEC Form D filed by Cadrenal Therapeutics Inc.

$ABT$CVKD Financials

Live finance-specific insights

Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott Hosts Conference Call for Third-Quarter Earnings

Abbott Declares 403rd Consecutive Quarterly Dividend

$ABT$CVKD Market Insights

Live Market Insights

Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers

Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims

Why Are Abbott Laboratories Shares Trading Lower?

$ABT$CVKD Leadership Updates

Live Leadership Updates

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

$ABT$CVKD Press Releases

Fastest customizable press release news feed in the world

$ABT$CVKD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Oppenheimer initiated coverage on Abbott Labs with a new price target

Piper Sandler initiated coverage on Abbott Labs with a new price target

Abbott Labs downgraded by Edward Jones

$ABT$CVKD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

$ABT$CVKD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EXECUTIVE VICE PRESIDENT Allen Hubert L exercised 157,421 units of Common shares without par value at a strike of $47.00 and sold $18,424,298 worth of Common shares without par value (157,421 units at $117.04) (SEC Form 4)

SEC Form 4 filed by Director Stratton John G

SEC Form 4 filed by Director Roman Michael F

Recent Analyst Ratings for
$ABT
$CVKD

$ABT
$CVKD
Large Ownership Changes

$ABT
$CVKD
SEC Filings

$ABT
$CVKD
Financials

$ABT
$CVKD
Market Insights

$ABT
$CVKD
Leadership Updates

$ABT
$CVKD
Press Releases

$ABT
$CVKD
Analyst Ratings

$ABT
$CVKD
FDA approvals

$ABT
$CVKD
Insider Trading